EMA Aesthetics , Ltd.

EMA Aesthetics, Ltd. specializes in multi-modality skin surface treatment systems, primarily focused on facial rejuvenation and skin resurfacing. Their portfolio includes the Préime DermaFacial series, which combines technologies like microcurrent stimulation and collagen induction to target skin texture, tone, and minor imperfections. These devices are designed for professional aesthetic use and deliver controlled energy or stimulation to improve skin appearance.

EMA Aesthetics, Ltd. is based in the United States. Their devices are developed and authorised within the U.S. regulatory framework, specifically adhering to FDA requirements for medical devices. Since their products fall under Class I and Class II classifications, they must comply with FDA pathways such as 510(k) clearance, De Novo authorisation, or UDI listing, depending on the device’s risk level and intended use.

EMA Aesthetics, Ltd.’s devices are listed in FDA registries, including the 510(k) Premarket Notification database and the UDI (Unique Device Identification) system. These registries ensure transparency and compliance tracking for devices authorised under the 510(k) pathway or through UDI listing, which are common for their Class I and Class II products. Listing in these databases confirms their legal presence in the U.S. market.

EMA Aesthetics, Ltd.’s devices are classified as Class I or Class II under FDA regulations. The classification depends on the device’s risk level and intended use—Class I typically includes lower-risk devices like some skin treatment systems, while Class II may apply to those with moderate risk, such as those requiring special controls (e.g., specific performance standards). The Préime DermaFacial series falls into these categories, meaning they undergo different authorisation pathways, such as 510(k) clearance for Class II or De Novo for novel low-to-moderate-risk devices.